Viking Therapeutics (VKTX) Other Non Operating Income (2014 - 2026)

Viking Therapeutics has reported Other Non Operating Income for 13 years, with the latest figure at $4.6 million in Q2 2026.

• Quarterly Other Non Operating Income fell 49.24% year-over-year to $4.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $25.2 million (down 38.91% YoY) and the FY2025 annual result came in at $33.7 million, down 17.71% from the prior year.
• Other Non Operating Income fell to $4.6 million in Q2 2026 per VKTX's latest filing, from $5.8 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $11.8 million in Q2 2024 and troughed at $142000.0 in Q1 2022.
• A 5-year average of $5.6 million and a median of $5.3 million in 2023 frame the typical range for Other Non Operating Income.
• The sharpest annual moves came in 2023 and 2026: Other Non Operating Income jumped 2168.84% in 2023, then sank 49.24% in 2026.
• Over 5 years, Other Non Operating Income stood at $724000.0 in 2022, then jumped by 546.41% to $4.7 million in 2023, then surged by 131.22% to $10.8 million in 2024, then tumbled by 34.61% to $7.1 million in 2025, then plunged by 35.34% to $4.6 million in 2026.
• According to Business Quant data, Other Non Operating Income over the past three periods registered $4.6 million, $5.8 million, and $7.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.